Leading Edge R&D:

InnaPhase SIGNS AGREEMENT WITH INVERESK RESEARCH GROUP INC

InnaPhase Corporation, a leading provider of enterprise technology solutions for life sciences, announced that the Inveresk Research Group, one of the largest contract research organizations in the world, has signed a license agreement to implement InnaPhase's Watson Laboratory Information Management System (LIMS). This most recent agreement provides Inveresk with Watson licenses for their European Headquarters in Tranent, Scotland and for CTBR in Montreal, Canada.

The Watson LIMS system is specifically designed to support DMPK/Bioanalytical studies in drug development while ensuring regulatory compliance with the FDA's 21 CFR Part 11 guidance on electronic records and signatures. Watson has an established track record of accelerating bioanalysis, sample management and regulatory compliance in pharmaceutical drug development.

"By further automating processes within our bioanalytical laboratories, we will gain a competitive advantage within our industry," said Gerry McGuire, Head of Bioanalysis at Inveresk's European Headquarters. "Watson LIMS will enable us to improve knowledge sharing, reduce sample turnaround times and accelerate the delivery of results to our customers."

"We are particularly happy that Inveresk has chosen Watson LIMS," said Peter Ryan, Chairman and CEO of InnaPhase Corporation. "Using InnaPhase technologies will enhance the Inveresk mission of providing excellence in communication of information, state of the art technologies and high quality of service to their valued customers."

InnaPhase Corporation also develops and markets the Enterprise Pharmacology Series (EP Series) and Kinetica products. The EP Series is a scalable technology solution that centralizes the analysis and management of early drug development data. This protocol-driven system provides intelligent data import and export, a flexible cross-study data-mining tool and powerful PK/PD data analysis, simulation and reporting capabilities. Kinetica is a powerful pharmacokinetic/pharmacodynamic analysis, simulation and reporting solution. Its intuitive interface and comprehensive tools facilitate increases in productivity by automating the routine processes required in PK/PD analysis. Watson LIMS, when used in conjunction with the EP Series and Kinetica, allows customers to take advantage of an end-to-end centralized, Part 11 compliant, solution that seamlessly supports early drug development from bioanalysis through PK/PD analysis to final report.

Inveresk Research is a leading provider of drug development services to companies in the pharmaceutical and biotechnology industries. The company headquarters is based in Tranent, Scotland, with facilities in the United States, Canada, England and seven other countries in Europe as well as Japan. For more information, see Inveresk Research Group on the worldwide Web at www.inveresk.com.

InnaPhase Corporation is a leading provider of enterprise technology solutions for life sciences. Its software and services enable global organizations to transform drug development data into enterprise-wide knowledge. InnaPhase solutions are rapidly becoming the industry standard for pre-clinical and clinical pharmacology. The InnaPhase solution suite helps transform early drug development data into enterprise-wide knowledge resulting in faster and more accurate decisions. With 15 years of scientific experience in advanced software and clinical database technologies, InnaPhase provides solutions for more than 800 customers in 45 countries, creating a competitive edge that allows customers to maximize and streamline their drug development pipeline. InnaPhase has locations in the United States and the United Kingdom. For more information, see InnaPhase on the worldwide Web at www.innaphase.com.

Contact InnaPhase Corporation, Karen Maul, 215-299-7400 x238, kmaul@innaphase.com.